587 related articles for article (PubMed ID: 24906642)
41. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.
Zhang R; Li Y; Wang Z; Chen L; Dong X; Nie X
Tumour Biol; 2015 Nov; 36(11):8585-92. PubMed ID: 26040768
[TBL] [Abstract][Full Text] [Related]
42. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
Ma G; Cai H; Gao L; Wang M; Wang H
World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1.
Pei K; Zhu JJ; Wang CE; Xie QL; Guo JY
Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4697-4704. PubMed ID: 27906433
[TBL] [Abstract][Full Text] [Related]
44. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
Fu J; Cai H; Wu Y; Fang S; Wang D
Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
47. miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.
Zhang Z; Zhang L; Yin ZY; Fan XL; Hu B; Wang LQ; Zhang D
Int J Clin Exp Pathol; 2014; 7(10):7236-41. PubMed ID: 25400821
[TBL] [Abstract][Full Text] [Related]
48. Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.
Li QQ; Xie YK; Wu Y; Li LL; Liu Y; Miao XB; Liu QZ; Yao KT; Xiao GH
Oncotarget; 2017 Feb; 8(7):12067-12080. PubMed ID: 28076844
[TBL] [Abstract][Full Text] [Related]
49. Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway.
Lu H; Kong J; Cai S; Huang H; Luo J; Liu L
Mol Biol Rep; 2024 Jun; 51(1):703. PubMed ID: 38822881
[TBL] [Abstract][Full Text] [Related]
50. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
Li W; Liu X; Zhang G; Zhang L
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
[TBL] [Abstract][Full Text] [Related]
51. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
52. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
Wang X; Dong K; Gao P; Long M; Lin F; Weng Y; Ouyang Y; Ren J; Zhang H
Cancer Biother Radiopharm; 2013 Feb; 28(1):45-50. PubMed ID: 23036084
[TBL] [Abstract][Full Text] [Related]
53. miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein.
Zhu X; Li D; Yu F; Jia C; Xie J; Ma Y; Fan S; Cai H; Luo Q; Lv Z; Fan L
Oncotarget; 2016 Mar; 7(11):13139-52. PubMed ID: 26909612
[TBL] [Abstract][Full Text] [Related]
54. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.
Kong M; Fan J; Dong A; Cheng H; Xu R
Acta Biochim Biophys Sin (Shanghai); 2010 Nov; 42(11):827-33. PubMed ID: 20978038
[TBL] [Abstract][Full Text] [Related]
55. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
[TBL] [Abstract][Full Text] [Related]
56. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
57. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9.
Dong Z; Zhong Z; Yang L; Wang S; Gong Z
Cancer Lett; 2014 Feb; 343(2):249-57. PubMed ID: 24099915
[TBL] [Abstract][Full Text] [Related]
59. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
[TBL] [Abstract][Full Text] [Related]
60. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
